Donanemab, an Alzheimer’s drug candidate produced by Eli Lilly, showed that it can slow cognitive decline by 35% in the company’s new Phase 3 study, but there are some safety risks – exemplified by two deaths that occurred during the trial that were attributed to brain swelling, according to the drug company.

In addition to the risk of brain swelling, the trial showed that close to one in four participants experienced abnormalities related to amyloid-related imaging.